Stocksigma LogoStocksigma Logo

Kilitch Drugs Divests Ethiopian Subsidiary For USD 12.86M Following Debt-To-Equity Conversion

Kilitch Drugs' board approved divesting its entire stake in Ethiopian subsidiary Kilitch Estro Biotech PLC (KEB) to state-owned HarmeeCare Pharmaceuticals

Kilitch Drugs Divests Ethiopian Subsidiary For USD 12.86M Following Debt-To-Equity Conversion

Kilitch Drugs India Ltd 路 Others (Uncategorized) 路 23 Oct 2026, 1:48 am

Kilitch Drugs Divests Ethiopian Subsidiary For USD 12.86M Following Debt-To-Equity Conversion Kilitch Drugs' board approved divesting its entire stake in Ethiopian subsidiary Kilitch Estro Biotech PLC (KEB) to state-owned HarmeeCare Pharmaceuticals for USD 14.0M total consideration, with USD 12.86M due to the company. Target completion is 31st Jan'27. Prior to divestment, Kilitch will convert up to INR 57.00 Cr outstanding debt into 1,66,472 KEB equity shares at Rs. 3,414 each by 30th Dec'26. In FY26, KEB contributed INR 47.57 Cr revenue (20.20% of consolidated) and negative INR 8.43 Cr net worth.

Original exchange filing (PDF)

More announcements from Kilitch Drugs India Ltd

All Kilitch Drugs India Ltd announcements